Please login to the form below

Not currently logged in
Email:
Password:

Abbott and AstraZeneca co-promote Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix

Abbott and AstraZeneca have entered into an agreement for the co-promotion of Abbott's lipid disorder treatment, Trilipix.

Under the terms of the agreement, AstraZeneca will gain non-exclusive rights to co-promote Trilipix in the US, excluding Puerto Rico.

Trilipix is used along with diet to lower triglycerides and LDL (bad) cholesterol, and increase HDL (good) cholesterol. It is also used in people who are at high risk of heart disease and are taking a statin medicine to control their LDL cholesterol.

"Abbott's portfolio of lipid therapies is designed to help physicians manage a patient's total lipid profile," said Jeffrey Stewart, divisional vice president, primary care, Abbott. "With AstraZeneca's established presence in the cardiovascular space, this agreement allows Abbott to expand visibility and education of Trilipix among physicians whose patients may benefit from this medication."

Jim Helm, vice president, cardiovascular, AstraZeneca US, said: "With clinical data to support its use in helping certain patients with mixed dyslipidemia to manage all three key lipids, Trilipix is another important therapeutic option we can now offer physicians."

This is the second co-promotion deal between the two pharmaceutical companies. In August 2008 they signed a non-exclusive deal for the co-promotion of AstraZeneca's Crestor in the US market. Specific financial terms of the Trilipix deal were not disclosed.

4th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics